FORMATION OF INNATE AND ADAPTIVE IMMUNE RESPONSE UNDER THE INFLUENCE OF DIFFERENT FLAVIVIRUS VACCINES

The review examines in a comparative perspective the key moments of formation of innate and adaptive immune responses to different types of current flavivirus vaccines: live attenuated against yellow fever virus and inactivated whole virus against tick-borne encephalitis virus. Particular attention is paid to the ability of these different vaccines, containing exogenous pathogen-associated molecular structures, to stimulate innate immunity. Live attenuated vaccine by infecting several subtypes of dendritic cells activates them through various pattern-recognition receptors, such as Tolland RIG-I-like receptors, which leads to significant production of proinflammatory cytokines, including interferon-α primary mediator of innate antiviral immunity. By simulating natural viral infection, this vaccine quickly spreads over the vascular network, and the dendritic cells, activated by it, migrate to the draining lymph nodes and trigger multiple foci of Tand B-cell activation. Inactivated vaccine stimulates the innate immunity predominantly at the injection site, and for the sufficient activation requires the presence in its composition of an adjuvant (aluminum hydroxide), which effects the formation and activation of inflammasomes, ensuring the formation and secretion of IL-1β and IL-18 that, in turn, trigger a cascade of cellular and humoral innate immune responses. We demonstrated the possibility of involvement in the induction of innate immunity, mediated by the inactivated vaccine, endogenous pathogenassociated molecular patterns (uric acid and host cell DNA), forming at the vaccine injection site. We discuss the triggering of Band T-cell responses by flavivirus vaccines that determine various duration of protection against various pathogens. A single injection of the live vaccine against yellow fever virus induces polyvalent adaptive immune response, including the production of cytotoxic T-lymphocytes, Th1and Th2-cells and neutralizing antibodies, which may persist for up to 40 years after the vaccination. To induce and maintain protective immunity, mediated by the inactivated vaccine against tick-borne encephalitis virus, it is required: triple immunization, which results in the production primarily of neutralizing antibodies, and subsequent booster injections every 3 years. We considered the potential use of the data on immunological mechanisms of action of current vaccines to generate new highly efficient vaccines.

1. Воробьева М.С., Расщепкина М.Н., Ладыженская И.П. Вакцины, иммуноглобулины и тест-системы для профилактики и диагностирования клещевого энцефалита // Вопросы вирусологии, 2007. Т. 52. С. 3036. [Vorob’yeva M.S., Rasschepkina M.N., Ladyzhenskaya I.P. Vaccines, immunoglobulins and test systems for the prevention and diagnosis of tick-borne encephalitis. Voprosy virusologii = Problems in Virology, 2007, Vol. 52, pp. 3036. (In Russ.)]

2. Медуницын Н.В. Вакцинология. М.: Триада-Х, 2010. 512 с. [Medunitsyn N.V. Vaccinology]. Moscow: Triada-X, 2010. 512 p.

3. Aberle J.H., Aberle S.W., Kofler R.M., Mandl C.W. Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J. Virol., 2005, Vol. 79, no. 24, pp. 15107-15113.

4. Bacchetta R., Gregori S., Roncarolo M.G. CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun. Rev., 2005, Vol. 4, pp. 491-496.

5. Barba-Spaeth G., Longman R.S., Albert M.L., Rice C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med., 2005, Vol. 202, pp. 1179-1184.

6. Barrett A.D.T., Teuwen D. Yellow fever vaccine – how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol., 2009, Vol. 21, pp. 1-6.

7. Basta S., Alatery A. The cross-priming pathway: a portrait of an intricate immune system. Scand. J. Immunol., 2007, Vol. 65, no. 4, pp. 311-319.

8. Blitvich B.J. Transmission dynamics and changing epidemiology of West Nile Virus. Anim. Health Res. Rev., 2008, Vol. 9, pp. 71-86.

9. Cassel S., Sutterwala F.S. Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur. J. Immunol., 2010, Vol. 40, no. 3, pp. 607-611.

10. Chun Y., Gallego M., Marches F., Zurawski S., Ramilo O., Zurawski G., Garcia-Sastre A., Banchereau J., Palucka A.K. Cross-presentation of Influenza virus vaccine antigens to CD8+ T cells in humanized mice. The FASEB Journal. 2008; 22:857.24.

11. Co M.D., Terajima M., Cruz J., Ennis F.A., Rothman A.L. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology, 2002, Vol. 293, pp. 151-163.

12. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity, 2010, Vol. 33, pp. 492-503.

13. Datta S.K., Raz E. Induction of antigen cross-presentation by Toll-like receptors. Springer Semin. Immunopathol., 2005, Vol. 26, pp. 247-255.

14. David-West T.S. Concurrent and consecutive infection and immunisations with yellow fever and UGMP359 viruses. Arch. Virol., 1975, Vol.48, pp. 21-28.

15. Del Giudice G., Pizza M., Rappuoli R. Molecular basis of vaccination. Mol. Aspects Med., 1998, Vol. 19, no. 1, pp. 1-70.

16. Demicheli V., Debalini M.G., Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database of Systematic Reviews, 2009, Vol. 1, CD000977.

17. Den Haan J.M., Bevan M.J. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J. Exp. Med., 2002, Vol. 196, no.6, pp. 817-827.

18. Desmet C.J., Ishii K.J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat. Rev. Immunology, 2012, Vol.12, pp. 479-491.

19. Donoso Mantke O., Escadafal C., Niedrig M., Pfeffer M. Tick-borne encephalitis in Europe, 2007 to 2009. Working Group for Tick-Borne Encephalitis Virus. Euro Surveill., 2011, Vol. 16, pii: 19976.

20. Eisenbarth S.C., Colegio O.R., O’Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature, 2008, Vol. 453, pp. 11221126.

21. Fehres C.M., Unger W.W.J., Garcia-Vallejo J.J., van Kooyk Y. Understanding the biology of antigen crosspresentation for the design of vaccines against cancer. Front. Immunol., 2014, Vol. 5, no. 149, pp. 1-10.

22. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., Moser J.M., Mehta R.S. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med., 2008, Vol. 205, pp. 3119-3131.

23. Gubler DJ. Emerging vector-borne flavivirus diseases: are vaccines the solution? Expert Rev. Vaccines, 2011, Vol. 10, no. 5, pp. 563-565.

24. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J. Dengue: a continuing global threat. Nat. Rev. Microbiol., 2010, Vol. 8 (12 Suppl.), pp. 7-16.

25. Halstead S.B., Thomas S.J. Japanese encephalitis: new options for active immunization. Clin. Infect. Dis., 2010, Vol. 50, no. 8, pp. 1155-1164.

26. Heinz F.X., Holzmann H., Essl A., Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine, 2007, Vol. 25, pp. 7559-7567.

27. Heinz F.X., Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine, 2012, Vol. 30, pp. 4301-4306.

28. Hoebe K., Janssen E., Beutler B. The interface between innate and adaptive immunity. Nat. Immunol., 2004, Vol. 5, pp. 971-974.

29. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol., 2008, Vol. 9, pp. 847-856.

30. Ishikawa T., Yamanaka A., Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine, 2014, Vol. 32, pp. 1326-1337.

31. Kool M., Soullié T., van Nimwegen M., Willart M.A.M., Muskens F., Jung S., Hoogsteden H.C., Hammad H., Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med., 2008, Vol. 205, pp. 869-882.

32. Kool M., Willart M.A., van Nimwegen M., Bergen I., Pouliot P. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity, 2011, Vol. 34, pp. 527-540.

33. Kreil T.R., Maier E., Fraiss S. Vaccination against tick-borne encephalitis virus, a flavivirus, prevents disease but not infection, although viremia is undetectable. Vaccine, 1998, Vol. 16, no. 11-12, pp. 1083-1086.

34. Kunz C. TBE vaccination and the Austrian experience. Vaccine, 2003, Vol. 21 (Suppl 1), pp. 50-55.

35. Kunze U. Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE). Vaccine, 2011, Vol. 29, pp. 1355-1356.

36. Leonova G.N., Ternovoi V.A., Pavlenko E.V. Evaluation of vaccine Encepur® Adult for induction of human neutralizing antibodies against recent Far Eastern subtype strains of tick-borne encephalitis. Vaccine, 2007, Vol. 25, pp. 895-901.

37. Leonova G.N., Pavlenko E.V. Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human. Vaccine, 2009, Vol. 27, pp. 2899-2904.

38. Leonova G.N. Evaluation of Immunological efficiency among patients vaccinated against tick-borne encephalitis. Flavivirus encephalitis / ed. D. Ruzek. In Tech, 2011, pp. 195-212.

39. Lindenbach B.D., Murray C., Thiel H.J., Rice C.M. Flaviviridae. Fields virology. 6th edition / ed. Knipe D.M., Howley P.M. Philadelphia: Lippincott Williams & Wilkins, 2013, pp. 712-746.

40. Lindsey N.P., Staples J.E., Lehman J.A., Fischer M. Surveillance for human West Nile virus disease – United States, 1999-2008. MMWR Surveill Summ, 2010, Vol. 59, pp. 1-17.

41. Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., Lekeux P., Coban C., Akira S., Ishii K.J., Bureau F., Desmet C.J. DNA released from dying host cells mediates aluminum adjuvant activity. Nature Med., 2011, Vol. 17, pp. 996-1002.

42. Mbow M. L., De Gregorio E., Valiante N. M., Rappuoli R. New adjuvants for human vaccines. Curr. Opin. Immunol., 2010, Vol. 22, pp. 411-416.

43. McKee A.S., Munks M.W., MacLeod M.K.L., Fleenor C.J., van Rooijen N., Kappler J.W., Marrack P. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol., 2009, Vol. 183, pp. 4403-4414.

44. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., Murali-Krishna K., Ahmed R. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity, 2008, Vol. 28, pp. 710-722.

45. Monath T.P., Cetron M.S., Teuwen D.E. Yellow fever vaccine. Vaccines / ed. Plotkin S.A, Orenstein W.A., Offit P.A. Elsevier Health Sciences, 2008, pp. 959-1055.

46. Murray K.O., Walker S., Gould E. The virology, epidemiology, and clinical impact of West Nile virus: a decade of advancements in research since its introduction into the Western Hemisphere. Epidemiol. Infect., 2011, Vol. 139, pp. 807-817.

47. Palucka A.K., Laupeze B., Aspord C. Immunotherapy via dendritic cells. Adv. Exp. Med. Biol., 2005, Vol. 560, pp. 105-114.

48. Pan C.-H., Chen H.-W., Huang H.-W., Tao M.-H. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8+cytotoxic T-cell responses. J. Virol., 2001, Vol. 75, no. 23, pp. 11457-11463.

49. Pedra J., Cassel S., Sutterwala F.S. Sensing Pathogens and Danger Signals by the Inflammasome. Curr. Opin. Immunol., 2009, Vol. 21, no. 1, pp. 10-16.

50. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunology, 2009, Vol. 9, pp. 741-747.

51. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nature Immunol., 2011, Vol. 131, pp. 509-517.

52. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med., 2006, Vol. 203, pp. 413-424.

53. Shrestha B., Ng T., Chu H.-J., Noll M., Diamond M.S. The relative contribution of antibody and CD8+T cells to vaccine immunity against West Nile encephalitis virus. Vaccine, 2008, Vol. 26, no. 16, pp. 2020-2033.

54. Siergist C.A. Vaccine immunology. Vaccines / ed. Plotkin S.A., Orenstein W.A., Offit P.A. Elsevier Health Sciences, 2008, pp. 17-36.

55. Spreafico R., Ricciardi-Castagnoli P., Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol., 2010, Vol. 40, pp. 638-642.

56. Takeuchi O., Akira S. Innate immunity to virus infection. Immunol. Rev., 2009, Vol. 227, pp. 75-86.

57. Vaccines against tick-borne encephalitis: WHO position paper. Weekly Epidemiol. Rec., 2011, Vol. 86, no. 24, pp. 241-256.

58. van Duin D., Medzhitov R., Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol., 2006, Vol. 27, pp. 49-55.

59. Webster D.P., Farrar J., Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect. Dis., 2009, Vol. 9, no. 11, pp. 678-687.

60. WHO: yellow fever / updated March 2014

61. Zepp F. Principles of vaccine design – Lessons from nature. Vaccine, 2010, Vol. 28, pp. 14-24.